First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.

Recruiting

Phase 1

Phase 2

First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.

Sponsor:

Corbus Pharmaceuticals Inc.

Code:

NCT06603844

Conditions

Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CRB-601 monoclonal antibody

Anti-PD-1 monoclonal antibody

Immune-priming single lesion SBRT

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information